Transcode Therapeutics (NASDAQ: RNAZ) — Company Overview, News & Financial Data
Transcode Therapeutics develops innovative cancer therapies targeting undruggable mutations, aiming to improve patient outcomes.
Transcode Therapeutics
Transcode Therapeutics (NASDAQ:RNAZ) is a biotech firm focused on developing groundbreaking therapies for cancer. Leveraging their innovative technology platform, they aim to disrupt cancer's ability to evade treatment by targeting and eliminating undruggable mutations and oncogenic pathways. Their operations span from early-stage research to potential clinical trials, with projects targeting a range of cancers. Transcode's objective is to dramatically improve patient outcomes by unlocking new avenues for treatment, providing hope where traditional therapies have faltered. Their commitment to excellence and innovation propels their quest to redefine cancer treatment for the modern era.
Snapshot
Operations
Products and/or services of Transcode Therapeutics
- Development of RNA oncology therapeutics for metastatic cancer, aiming to inhibit tumor growth.
- Creation of TTX-MC138, a therapeutic targeting microRNA involved in cancer cell proliferation.
- Research on nanoparticle-based delivery systems for precision targeting of cancer cells.
- Collaboration on biomarker-driven precision medicine projects for personalized cancer treatment.
- Advancing TTX-siPDL1, a siRNA therapy designed to modulate immune checkpoints in cancer.
- Exploration of TTX-mRNA therapeutics for reprogramming cancer cells to a less malignant state.
Transcode Therapeutics executive team
- Philippe P. CalaisCEO & Executive Chairman of the Board
- Zdravka MedarovaScientific Co-Founder & Chief Scientific Officer
- Anna MooreScientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board
- John A. TattoryInterim Chief Financial Officer
- Daniel R. VlockChief Medical Officer
- Michel JanicotConsulting Head of Translational Science
Latest news about Transcode Therapeutics
Key financials
Reported results for Transcode Therapeutics, in USD.
- Market cap
- 26.6M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -52.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -28M | -34.7M | |
| 0 | -15.7M | -16.8M | |
| 0 | -19.4M | -18.5M | |
| 0 | -18.7M | -17.6M |